New York Life Investment Management LLC Has $6.74 Million Stock Position in Becton, Dickinson and Company $BDX

New York Life Investment Management LLC raised its stake in Becton, Dickinson and Company (NYSE:BDX) by 1.6% during the 2nd quarter, Holdings Channel reports. The fund owned 39,122 shares of the medical instruments supplier’s stock after acquiring an additional 630 shares during the period. New York Life Investment Management LLC’s holdings in Becton, Dickinson and Company were worth $6,739,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently bought and sold shares of the stock. Diversified Trust Co raised its holdings in Becton, Dickinson and Company by 4.7% in the 1st quarter. Diversified Trust Co now owns 1,188 shares of the medical instruments supplier’s stock valued at $272,000 after acquiring an additional 53 shares during the period. Bill Few Associates Inc. raised its holdings in Becton, Dickinson and Company by 0.7% in the 2nd quarter. Bill Few Associates Inc. now owns 7,906 shares of the medical instruments supplier’s stock valued at $1,362,000 after acquiring an additional 55 shares during the period. Meadow Creek Wealth Advisors LLC raised its holdings in Becton, Dickinson and Company by 5.4% in the 1st quarter. Meadow Creek Wealth Advisors LLC now owns 1,161 shares of the medical instruments supplier’s stock valued at $266,000 after acquiring an additional 59 shares during the period. Stephens Inc. AR raised its holdings in Becton, Dickinson and Company by 0.3% in the 1st quarter. Stephens Inc. AR now owns 18,578 shares of the medical instruments supplier’s stock valued at $4,255,000 after acquiring an additional 59 shares during the period. Finally, Plancorp LLC raised its holdings in Becton, Dickinson and Company by 4.1% in the 1st quarter. Plancorp LLC now owns 1,499 shares of the medical instruments supplier’s stock valued at $343,000 after acquiring an additional 59 shares during the period. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Stock Performance

NYSE BDX opened at $181.49 on Thursday. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $52.02 billion, a price-to-earnings ratio of 32.64, a P/E/G ratio of 1.44 and a beta of 0.25. The firm’s 50 day simple moving average is $189.14 and its 200 day simple moving average is $183.39. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. The business had revenue of $5.32 billion for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. As a group, research analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on BDX shares. Wall Street Zen raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Argus raised their target price on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Piper Sandler reaffirmed a “neutral” rating and set a $200.00 target price (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Finally, Wells Fargo & Company raised their target price on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a report on Friday, August 8th. Three analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $205.40.

Insider Activity

In related news, Director Claire Fraser sold 917 shares of the stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the sale, the director owned 22,226 shares in the company, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In the last quarter, insiders have sold 1,895 shares of company stock worth $358,995. Company insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.